DD202-114

DD202-114 is a potent and selective GLP1R agonist. DD202-114 inhibits hERG with an IC50 of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC50 of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity[1][2].

Product Specifications

CAS Number

[2886728-09-0]

UNSPSC

12352005

Target

Cytochrome P450; GLP Receptor; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/dd202-114.html

Purity

98.47

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C2C(N(C(CN3CCC(C4=NC(OCC5=C(C=C(C=C5)C6COC6)F)=CC=C4)CC3)=N2)C[C@@H]7CCO7)=C1)O

Molecular Formula

C33H35FN4O5

Molecular Weight

586.65

References & Citations

[1]Zhang Z, et al. Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor. J Med Chem. 2024 Sep 12;67 (17) :14820-14839.|[2]Dong G, et al. Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist. J Med Chem. 2025 May 8;68 (9) :9555-9583.